active
ACTIVE SINCE: 2014
Back to Collaborations

E1018 treatment in Malaria

E1018 treatment as novel PfcPheRS inhibitor for Malaria
SDGS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
PARTNERING WITH:
SEE ALL PARTNER ORGANIZATIONS
Academia or research institute 2
Objectives
  • Preclinical development of a novel mechanism-of-action antimalarial

In September 2014, Eisai entered into a joint research agreement with the Broad Institute (Cambridge, Massachusetts, United States, “Broad”) to develop a new antimalarial treatment. Eisai and Broad work together to jointly evaluate compounds screened from Broad’s library and identified E1018, a compound with the potential to be used in clinical trials. The goal of this research is to develop an oral medicine that will rapidly cure malaria, and by interrupting the transmission of plasmodium (the parasite that causes malaria), will prevent malaria reinfection.

Results and milestones

Our project leverages a structure-based approach that has enabled identification of next generation inhibitors of a high-priority antimalarial target, PfcPheRS. This builds on and is informed by the pioneering work of our collaborative project team to develop the first clinical candidate against this target. The next-generation program is expected to retain the key advantages of that frontrunner program – namely a novel MoA, multi-stage activity and predicted single-dose efficacy – with the potential for improvements in safety profile and cost of treatment.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Men
  • Women
  • People with low incomes
Partner organizations
Academia or research institute

Broad Institute

International Centre for Genetic Engineering and Biotechnology

Geographic Reach

Global Commitment

Disease Area

Infectious and Parasitic Disease

  • Malaria
    of